Newsletter
| Promoter: | PennyStockLocks.com | Paying Party: | Equities Awareness Group |
| Stocks covered: | Compensation: | Avg $ Volume for Period: |
| BMSN | $13500 | 49310 |
| Max Profit: 2.70 % | Gain at close: -24.32 % | |
| *We think that this promoter is a part of a group of promoters. | ||
|
Members, A few days ago we told you that we have been scanning the market hard in search of the perfect alert to kick-off the fall season... Well after days of research we have found what seems like the perfect pick to start the season off with... We know how much you love those low priced subpennies, and their monster gain potential... So its no surprise that we're kicking off Fall with a red-hot subpenny alert! Please turn your immediate attention to BMSN (Bio-Matrix Scientific Group Inc.)! This red hot Bio-Tech company is screaming breakout! It's not often we see a company operating in a $32 Billion industry trading under a penny... So you shouldn't be surprised when we tell you that BMSN may not be trading under a penny for much longer... BMSN caught our attention today when we watched it shoot up 25% on heavy volume... The company closed well in the green, which is usually strong sign of bullish momentum to come! The technicals look excellent right now, with the analyst's at barchart.com upgrading BMSN to a "Strong Buy" for traders in the short, medium, and long term! Now remember BMSN is a subpenny... That means even the smallest move in price could equate to some serious gains... Trading at just $0.0034, If BMSN were to hit $0.01, which it easily could, that would equate to nearly +200% in gains! How many times have we watched our subpenny alerts explode for triple, sometimes quadruple digit gains in just one day??? Right now BMSN has triple digit gains written all over it! Now if that isn't enough to grab your attention, here is another reason why BMSN should be the only alert on your radar tomorrow... We just confirmed that the company is set to release news tomorrow that could grab the attention of the entire market.. Can you imagine the gains BMSN could show us tomorrow once this news is dropped? We've watched BMSN move up more than 1,400% from its 52-week low of 0.0002 since December of last year..... Could tomorrow be the start of its next +1,000% run? We certainly don't want you to miss out on this huge profit opportunity, that is why we are urging all members to immediately put BMSN on the top of their watch list, and be ready early tomorrow at 9:30am EST! Start your research now, and view BMSN's Full Profile, Latest News, and Chart below: Company: Bio-Matrix Scientific Group Inc. Symbol: BMSN Alert PPS: $0.0034 Website: www.regenbiopharma.com Bio-Matrix Scientific Group Inc. (OTCQB: BMSN) is a biotechnology company focused on the development of regenerative medicine therapies and tools. The Company is specifically focused on human therapies that address unmet medical needs. Specifically, Bio-Matrix Scientific Group Inc. is looking to increase the quality of life through therapies involving stem cell treatments. These treatments are focused in areas relating to lung, heart, circulatory system and other internal organs. BMSN is pursuing relationships with hospitals, medical institutes, research firms and biotechnology companies to assist in stem cell research, cell culturing and Regenerative Medicine therapies. BMSN’s facilities are available for processing, culturing and storage of specimens. Also, under certain situations, the Company has laboratories available to organizations conducting research. BMSN's subsidiary Regen BioPharma, Inc. is a biotechnology company focused on identifying undervalued regenerative medicine applications in the stem cell space and rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials.
The company released big news today when they announced that they are currently developing research plans for their breast cancer immunotherapeutic product, dCellVax. This cell therapy is based on patent # 8,389,708 obtained from Dr. Wei-Ping Min of the University of Western Ontario as well as an international patent portfolio licensed from Benitech Biopharma Ltd.
This is huge news as it is a huge step toward cementing BMSN's place in a multi-billion dollar breast cancer treatment market!
Strong Stem Cell Market Outlook Could Mean Huge Revenues For BMSN!
A new report by visiongain predicts that the overall world market for stem cell technologies in medicine will reach $7.3 billion for 2014. That market will be stimulated by new treatments and increasing use of related products in drug development. Those findings appear in Stem Cell Technologies: World Market Outlook 2012-2022, published in May 2012. Visiongain is a business information provider based in London, UK.
Visiongain forecasts that the stem cells market will expand rapidly from 2012 to 2022, achieving multi-billion-dollar revenues worldwide. More than 200 companies operate in that field. The next ten years will result in many new medical products and uses for stem cells. The period to 2022 will establish the foundations of a therapeutic revolution, the report concludes.
Haematopoietic stem cell transplantation is an established treatment for blood cancers. Revenues from transplants of bone marrow, peripheral blood and umbilical cord blood form much of the market in 2012. Banking of umbilical cord blood (other stem cell-containing blood units) and culturing and processing of stem cells for laboratory work are the other established business areas in 2012. That commercial activity is only the start, the report argues, with stem cell technologies poised for important advances by 2020.
Dr James Evans, a pharmaceutical industry analyst in visiongain, explains: “Stem cell technologies have been hyped for a long time, but it’s only now that we’re going to see the first approved products, treatments based on mesenchymal stem cells or improvements to stem cell transplants. Stem cell-based innovations are likely in the treatment of vascular diseases, autoimmune diseases, diabetes, dry AMD and other serious disorders. Some of these breakthroughs will be a commercial reality by 2022."
“The use of stem cells in laboratory assays for drug development is a strong opportunity for the biotechnology industry. Stem cells offer an improved way to model diseases in vitro, identify candidate drugs and perform toxicity testing and other assays. With drug development costs and failures such a concern for the pharmaceutical industry, that segment will be important to the overall stem cells market, representing around a third of its revenues by 2022, our study predicts.”
With the forecast for the Stem Cell Market looking so positive right now, BMSN could be well on its way to record revenue numbers!
If BMSN were to tap into this booming market we could see its PPS explode for record breaking profits!
We don't anticipate BMSN to be trading under a penny for much longer...
We are urging all members to immediately put BMSN on the top of their watchlist, and to be ready early tomorrow at 9:30am EST...
Remember The first step to becoming a successful penny stock trader is opening up a brokerage account if you haven't done so already you can start by clicking here. Sincerely, The PennyStockLocks Team P.S. Share the wealth and forward this email to all your fellow traders who have yet to join the fastest growing network of serious traders on the web. ----------------------------------------------------- Bio-Matrix Scientific Group's Subsidiary, Regen BioPharma Announces dCellVax Breast Cancer Immunotherapeutic Product
8:30a ET September 25, 2013 (Market Wire)
Bio-Matrix Scientific Group Inc. (OTCQB: BMSN) announced today that its Regen BioPharma subsidiary is currently developing research plans for its breast cancer immunotherapeutic product, dCellVax. This cell therapy is based on patent # 8,389,708 obtained from Dr. Wei-Ping Min of the University of Western Ontario as well as an international patent portfolio licensed from Benitech Biopharma Ltd.
The dCellVax therapeutic product is based on extracting blood from patients, growing a specialized type of immune cell from the blood called the "dendritic cell" and then subsequently genetically modifying the dendritic cell to become resistant to cancer's immune suppressive activity. It is known that cancer modifies the immune system by producing proteins which result in immune suppression. One such protein which cancer stimulates is an enzyme, indolamine 2,3 deoxygenase (IDO), which cancer turns on in dendritic cells. While dendritic cells are usually immune stimulators, dendritic cells found in cancer patients suppress the immune system as a result of expressing IDO.
Researchers at the University of Western Ontario, led by Dr. Wei-Ping Min, have demonstrated that using a genetic blockade of IDO in dendritic cells makes them resistant to the effects of cancer, and allows them to stimulate potent immune responses against tumors. The use of these modified dendritic cells has been previously demonstrated and published in peer-reviewed journals in the melanoma and breast cancer mouse models(1),(2).
Regen is currently working with the contract research organization (CRO) bioRASI LLC together with Dr. Wei-Ping Min's group at manufacturing human dCellVax. Additionally, the recruitment of David Suhy, PhD from Benitec's subsidiary Tacera to Regen's Scientific Advisory Board will provide in-house clinical translation experience in the area of genetic based therapies. Dr. Suhy was essential in the development of the gene-based hepatitis drug in collaboration with Pfizer.
Regen identified the following milestones in the anticipated further development of dCellVax:
a) Generation of human dCellVax: 2 months b) In vitro demonstration of dCellVax efficacy: 1 month c) FDA-requested toxicology: 4 months
d) IND submission: 1 month
Regen BioPharma's Chairman & CEO David Koos commented "I am excited to see the progress our company is making. Currently in our pipeline we have two products under development, HemaXellerate (a treatment for aplastic anemia) and now dCellVax (a cancer immuno-therapeutic). I believe these two areas represent a solid foundation for our company."
About Regen BioPharma: Regen BioPharma, Inc., a subsidiary of Bio-Matrix Scientific Group, Inc. (OTCQB: BMSN), is a biotechnology company focused on identifying undervalued regenerative medicine applications in the stem cell space and rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. For more information refer to the company's website http://www.regenbiopharma.com/
Follow Us On: This report/release/advertisement is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our site, or joining our email list. PLEASE NOTE WELL: Pennystocklocks.com and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever. Pennystocklocks.com does not provide trading, investment or tax advice, and readers shall not rely on statements by Pennystocklocks.com employees which purport to provide such advice. Full disclaimer can be read at http://www.Pennystocklocks.com/Disclaimer/ PennyStockLocks.com has been compensated $13,500.00 by Equities Awareness Group LLC., on 09-26-2013 for this one-day profile of BMSN. The third party may have shares and may liquidate it which may negatively affect the stock price. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company.
|
